Ohio State Navbar

Clinical Trials


The talented faculty within the Division of Medical Oncology are proud to be a part of the Comprehensive Cancer Center Network  and one of only five centers in the nation that is approved for Phase I and Phase II clinical Trials. Our team  currently has numerous clinical trials open to accrual  focusing on cancers ranging from non-small cell lung cancer, pancreatic cancer, metastatic breast cancer, metastatic melanoma and much more.  If you are interested in learning more about our current clinical trials, please use the search feature for more information.

 

Current Clinical Trials

 
  • A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross- Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer (Tanios Bekaii-Saab, MD)
     
  • Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted TherapyPhase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy (Manisha Shah, MD)
     
  • A Multicenter, Two-Stage, Phase II Study Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) vs. Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy (Manisha Shah, MD)
     
  • A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-Small Cell Lung Cancer and BRAF Mutations (Miguel Villalona, MD)
     
  • A Phase III, Randomized, Double-Blind Study of Dabrafenib (GSK2118436) in Combination with Trametinib (GSK1120212) vs. two Placebos in the Adjuvant Treatment of High-Risk BRAF V600 Mutation-positive Melanoma After Surgical Resection (Kari Kendra, MD, PhD)
     
  • A Phase II Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib (Tanios Bekaii-Saab, MD)
     
  • Decision Impact Analysis of Foundation Medicine's Next Generation Sequencing Test in Advanced Solid Tumor Malignancies (Erin Macrae, MD)
     
  • Randomized, Phase II Study of MK-3475 vs. Chemotherapy in Patients with Advanced Melanoma (Kari Kendra, MD, PhD)
     
  • Randomized Phase II Study Comparing Cabozantinib (NSC #761968 AND IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma  (J. Paul Monk, PhD)
     
  • Open-Label, Multicenter, Phase II Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-Line Therapy to Patients With Non-Small Cell Lung Cancer (Greg Otterson, MD)
     
  • Phase I Trial Studying the Side Effects and Best Dose of Dabrafenib and Pazopanib Hydrochloride When Given Together in Treating Patients With Advanced Malignant Tumors. Dabrafenib and Pazopanib Hydrochloride May Stop the Growth of Tumor Cells by Blocking Some of the Enzymes Needed for Cell Growth (Manisha Shah, MD)
     
  • Decision Impact Analysis of Foundation Medicine's Next Generation Sequencing Test in Advanced Solid Tumor Malignancies (Erin Olson, MD)
     
  • Randomized, Phase II, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High-Risk HER2+ Urothelial Carcinoma (Amir Mortazavi, MD)
     
  • Phase II Study of Oral Rigosertib in Patients with Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma (Maura Gillison, MD)
     
  • Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer After Prior Chemotherapy (Tanio Bekaii-Saab, MD)
     
  • Phase I/II Study of the ALK Inhibitor CH5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer (Bo Chao, MD)
     
  • Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients With Advanced Cancer (Greg Otterson, MD)
     
  • Multicenter, Open-label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma (Kari Kendra, MD, PhD)
     
  • Prospective Randomized Phase II Trial of Pazopanib (NSC #737754, IND #75648) vs. Placebo in Patients With Progressive Carcinoid Tumors (Manisha Shah, MD)
     
  • Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Bo Chao, MD)
     
  • Phase II Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations (Bo Chao, MD)
     
  • Decision Impact Analysis of Foundation Medicine's Next Generation Sequencing Test in Advanced Solid Tumor Malignancies (Erin Olson, MD)
     
  • Single-Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple-Negative Breast Cancer (Erin Olson, MD)